Comprehensive Immunoprofiling of High-Risk Oral Proliferative and Localized Leukoplakia
Glenn J. Hanna(Dana-Farber Cancer Institute), F. Stephen Hodi(Harvard University), Kristen D. Felt(Brigham and Women's Hospital), Sook‐Bin Woo(Dana-Farber Brigham Cancer Center), Madison Turner(Dana-Farber Cancer Institute), Charles T. Quinn(Dana-Farber Cancer Institute), Scott J. Rodig(Brigham and Women's Hospital), Alessandro Villa(Mario Negri Institute for Pharmacological Research), Ravindra Uppaluri(Brigham and Women's Hospital), Kathleen L. Pfaff(Dana-Farber Cancer Institute), Robert I. Haddad(Georgetown University), Yonghui Jia(Brigham and Women's Hospital), Nikhil Mistry(St. Michael's Hospital), Ann Marie Egloff(Brigham and Women's Hospital)
Cited by 28
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k